Edison Investment Research - ReNeuron Group (RENE) ReNeuron Group - A step forward on the Exosome delivery platform

Report

Edison Investment Research

Sean Conroy

ReNeuron Group - A step forward on the Exosome delivery platform

ReNeuron Group has generated in vivo data for CustomEX, marking a key step towards validating its proprietary stem cell-derived exosome platform. While the precise nature of the data is yet to be disclosed, we view the update as an encouraging sign and believe that it could improve traction for discussions for collaborations and partnerships, a key near-term goal for the company. ReNeuron now aims to broaden its capabilities by focussing on the functional delivery of specific therapeutics payloads, which we believe could include siRNA, mRNA, proteins, small molecules and genes, based on previous studies. Updates are expected in due course, potentially representing an important catalyst for investor attention, provided the data continue to be positive.

15/09/2023 1 EN

Underlying

ReNeuron Group

Reneuron Group researches and develops therapies using stem cells. Co.'s products include: CTX cells for stroke disability, which is its therapeutic candidate for the treatment of patients left disabled by the effects of a stroke; human retinal progenitor cells (hRPCs) for retinitis pigmentosa (RP), which is its therapeutic hRPC candidate for the treatment of RP, a blindness-causing disease of the retina; hRPCs for cone-rod dystrophy, which is a hRPC therapeutic candidate across a range of genetic diseases of the eye; and CTX-derived exosomes, which is its exosomes nanomedicine platform that generates early pre-clinical data in cancer.

See profile

GB00BF5G6K95 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

ReNeuron Group - Termination of coverage

Edison Investment Research is terminating coverage on ReNeuron Group (RENE). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 22, 2024 March 22, 2024 1 EN

Hardman & Co

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (-8.2%). Only 15 companies in our index saw share prices rise in 2023, four of these benefiting from ...

January 12, 2024 January 12, 2024 1 EN

EQS Group AG

Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™

Edison Investment Research Limited Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ 27-Nov-2023 / 08:53 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 27 November 2023 Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ ReNeuron has announced its H124 results (to end-September 2023), reaffirming its commitment to advance CustomEX™, its proprietary stem cell-derived exosome delivery platform. The key operational update from the period included in vivo data...

November 27, 2023 November 27, 2023 1 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

May 17, 2024 May 17, 2024 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

May 17, 2024 May 17, 2024 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ReNeuron Group - A step forward on the Exosome delivery platform

ReNeuron Group - Termination of coverage

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

AAC Clyde Space - Solid start to the year with further order growth

Tinexta - Typical seasonality in Q124

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe